Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis.
Yeong-Min LeeSoon-Hee LeeTae-Hee KimYoung Ah ParkYoung-Ah ParkJae-Sik JangPublished in: Cardiology journal (2020)
Both GLP-1 agonists and SGLT-2 inhibitors showed comparable cardiovascular outcomes in patients with type 2 diabetes. However, the SGLT-2 inhibitors were associated with more pronounced reduction of hospitalization for HF and lower risk of treatment discontinuation than GLP-1 agonists.
Keyphrases